RSS Feeds
Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic Arthritis
- James M. Pellissier, PhD;
- Douglas J. Watson, PhD;
- Sheldon X. Kong, PhD; and
- Walter L. Straus, MD, MPH
- From Merck & Co., West Point, PA 19486.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Spiegel and colleagues (1) examined the cost-effectiveness of cyclooxygenase-2 inhibitors compared with generic naproxen among patients with chronic arthritis. The authors critiqued our health economic analysis comparing rofecoxib with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and in doing so misstated both our methods and conclusions (2). We would like to address these errors.
Spiegel …
